An expansion of the trinucleotide repeat region in the FMR1 gene increases a woman’s risk of developing a condition called fragile X-associated primary ovarian failure (FXPOI). In this disease, the CGG trinucleotide repeat in the FMR1 gene is repeated between 55 and 200 times and is known as a premutation. Women who develop FXPOI may experience irregular menstrual cycles, the inability to have children (infertility), early menopause, and elevated levels of a hormone known as follicle-stimulating hormone (FSH).
Approximately 16% to 20% of women with this premutation have FXPOI, which causes abnormal menstrual cycles and elevated FSH levels before the age of 40 and often causes infertility.
Step-by-Step
How does it work?
1.
Get in touch with us or your doctor.
2.
We carry out genetic counselling and get your informed consent for the test.
3.
Blood is drawn at one of our centers.
4.
Our team or your doctor will contact you to discuss the results.
Who is it for?
When is it recommended?
Women with an ovarian reserve lower than that corresponding to their age.
Women experiencing early menopause.
Women with a family history of fragile X syndrome or one of its related disorders.
The FMR1 test allows us to determine the risk that descendants would have of inheriting an expanded allele and, therefore, the risk that they might have diseases related to the FMR1 gene, fragile X syndrome, fragile X-associated primary ovarian failure (FXPOI), or ataxia related to the FMR1 gene.